Hello,

Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board.

Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox.

You’re just two quick steps away from completing your sign-up:

1. Make sure our emails go to your inbox

Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary

Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP

Other providers:
Reply to this message and add [email protected] to your contacts

2. Confirm your subscription

Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter.

Confirm your subscription here.

After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link.

Thanks again for subscribing—we look forward to being part of your investing journey.

Matthew Paulson
Founder and CEO, MarketBeat.

P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.

The Cannabis Sector's Billion-Dollar Tax Cut

Author: Jeffrey Neal Johnson. Date Posted: 4/23/2026.

On the heels of the executive order to fast-track research into psychedelic drugs, a second federal policy shift on April 23, 2026, is rippling through the cannabis sector. Many on Wall Street, however, are misunderstanding the real catalyst: moving state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act is not the same as federal legalization.

Instead, this is a surgical financial change — buried in the U.S. tax code — that could unlock billions in value for a select group of companies. For investors, the move rewrites the industry's rulebook, shifting the sector from speculative hope toward tangible cash flow and creating a clearer playbook for identifying potential profitability.

How the Death of 280E Changes Everything

The #1 stock to buy BEFORE the June S-1 filing (Ad)

When the SpaceX IPO launches, most retail investors will be locked out. The banks, funds, and insiders get in early - while everyone else waits on the sidelines.

But one small infrastructure supplier - a critical piece Musk can't scale the Colossus network without - is still trading well under institutional radar. A new briefing reveals the name and ticker at no cost.

Get the SpaceX infrastructure stock name and ticker here

For more than a decade, U.S. cannabis companies have been uniquely penalized by Internal Revenue Code Section 280E. Originally designed in the 1980s to prevent illegal drug traffickers from claiming deductions, the rule was applied to state-legal cannabis businesses.

Put simply, licensed companies could not deduct ordinary and necessary business expenses from taxable income. Imagine a typical retail business being unable to deduct store rent, payroll, or marketing. Cannabis operators were thus taxed on gross profit rather than net income, producing crushing effective tax rates that often exceeded 70%.

The administrative reclassification to Schedule III effectively nullifies 280E for licensed medical operators. That single change lets them operate like other businesses and reduces their effective tax rate toward the standard corporate rate of roughly 21%.

The valuation implications are direct and powerful. This policy change functions like a large, non‑dilutive infusion of cash to company balance sheets: it should immediately improve net income, lift earnings per share (EPS), and provide management teams with hundreds of millions in newly available capital. Companies can use that capital to fund growth, pay down debt, or return money to shareholders instead of sending it to the IRS.

The New Kings of Cannabis Cash Flow

Despite sector-wide excitement, the fiscal windfall will not benefit every company equally. While the move to Schedule III is broad, the most pronounced advantage — a significant, non-dilutive liquidity boost — will accrue primarily to leading U.S. multi-state operators (MSOs) with dominant revenue streams and solid operational infrastructure.

The Profitability King

Green Thumb Industries (OTCMKTS: GTBIF) stands out. It was one of the few major MSOs to consistently generate positive net income even under the full weight of 280E, reporting trailing net income of $114.15 million.

With a price-to-earnings ratio near 15x before the change, its profitability could expand materially. That increased cash flow could let Green Thumb invest more heavily in marketing its consumer brands, such as Rythm and Dogwalkers, potentially accelerating market-share gains in key states.

The Scale and Shareholder-Return Play

With over $1.27 billion in annual sales, Curaleaf (OTCMKTS: CURLF) has the scale to realize some of the largest tax savings in the industry. The company underscored this new financial reality by announcing an $83 million share buyback program.

A repurchase is a classic move for a mature company with excess cash. The timing — announced days before the policy shift — may signal management's confidence, even before the official end of the 280E burden. Curaleaf’s shift from survival mode toward returning capital could attract value-oriented investors.

The High-Leverage and Strategic Plays: Trulieve, Verano, and Cresco Labs

Other MSOs can use their tax savings for aggressive expansion. Trulieve Cannabis (OTCMKTS: TCNNF), dominant in Florida with strong political ties, may deploy funds to fortify its position ahead of potential adult-use legalization there.

Cresco Labs (OTCMKTS: CRLBF), which recently won a medical license in Texas, and Verano Holdings (OTCMKTS: VRNOF), which streamlined its structure by redomiciling to Nevada, now have more capital to fund expansion without taking on as much debt or diluting shareholders.

The Tilray Contrast: Know What You Own

When cannabis headlines break, many investors gravitate toward familiar, NASDAQ-listed names like Tilray Brands, Inc. (NASDAQ: TLRY), assuming over-the-counter (OTC) names are too risky. Tilray is among the most liquid and widely held stocks in the sector and is often used to gain broad exposure to industry sentiment.

But Tilray’s business model differs materially from U.S. MSOs. Its operations are primarily focused on the Canadian adult-use market, international medical markets in Europe, and a growing U.S. presence centered on craft beverage brands like SweetWater Brewing.

Because Tilray was not subject to the punitive U.S. 280E tax, it does not receive the same direct financial uplift from this specific policy change. For investors assessing impacts from Schedule III, Tilray may act more like a sympathy trade than a primary beneficiary.

The Green Wave: A New Era for Cannabis Profits

The Schedule III move is a partial win, but potentially the most important financial victory the U.S. cannabis industry could have hoped for. It does not legalize cannabis federally, enable interstate commerce, or automatically clear the path for immediate uplisting to major U.S. exchanges like the NASDAQ. Those remain significant hurdles.

By normalizing the tax treatment, however, the policy gives the strongest U.S. operators the ability to build financial fortresses. While federal banking reform is still necessary, it becomes less urgent now that leading companies can generate internal cash flow to fund operations and expansion.

The investment playbook has shifted: the focus moves from betting on broad policy reform to analyzing fundamentals of U.S. MSOs that can convert large tax savings into sustainable earnings.

While the industry has not received a full legal all-clear, it has gained an official financial one. Investors interested in the space should consider adding top U.S. MSOs to their watchlists and watch upcoming quarterly earnings for management's first official guidance in this post-280E environment.